Investigational drug · Phase 2
Lorigerlimab
Also called: MGD019
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
9
Any phase or sponsor naming "Lorigerlimab"
First trial start
2023
Sep 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Lorigerlimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Platinum-resistant Ovarian Cancer
- Platinum-Resistant Fallopian Tube Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Clear Cell Adenocarcinoma of Ovary
- Clear Cell Adenocarcinoma of Vulva
- Clear Cell Adenocarcinoma of Vagina
- Clear Cell Adenocarcinoma of Cervix
- Clear Cell Adenocarcinoma of Uterus
- Clear Cell Adenocarcinoma of Fallopian Tube
- Clear Cell Adenocarcinoma of Peritoneum
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Lorigerlimab" as an intervention, largest first.
MacroGenicsIndustry
NCT03761017 · 162 participants · Start Dec 12, 2018 · Primary completion Aug 29, 2024
Drug: Lorigerlimab · For: Squamous Cell Non Small Cell Lung Cancer; Prostate Cancer Metastatic; Cutaneous Melanoma and 3 more
Sites: Chicago, Illinois; Boston, Massachusetts; Grand Rapids, Michigan · 39 sites in all
- A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate CancerPivotal-lookingCompleted
MacroGenicsIndustry
NCT05848011 · 154 participants · Start Sep 28, 2023 · Primary completion Feb 19, 2026
Drug: lorigerlimab; docetaxel and 1 more · For: Androgen-Independent Prostatic Cancer; Androgen-Independent Prostatic Neoplasms; Prostate Cancer Recurrent and 6 more
Sites: Miami, Florida; Orlando, Florida; Boston, Massachusetts · 61 sites in all
MacroGenicsIndustry
NCT06730347 · 80 participants (planned) · Start May 1, 2025 · Primary completion Jul 2027
Drug: Lorigerlimab · For: Platinum-resistant Ovarian Cancer; Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma and 8 more
Sites: Los Angeles, California; New Orleans, Louisiana; Grand Rapids, Michigan · 16 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT05475171 · 60 participants (planned) · Start Dec 13, 2022 · Primary completion Jun 30, 2028
Drug: Lorigerlimab · For: Metastatic Cancer; Cervical Cancer
Sites: Houston, Texas
University of MiamiAcademic, hospital or other
NCT07565155 · 40 participants (planned) · Start Jan 1, 2027 · Primary completion Jan 1, 2032
Drug: Lorigerlimab · For: Pancreatic Adenocarcinoma; Homologous Recombination Deficiency
Sites: Miami, Florida
MacroGenicsIndustry
NCT05293496 · 31 participants · Start Apr 19, 2022 · Primary completion Jun 24, 2025
Drug: vobramitamab duocarmazine; lorigerlimab · For: Advanced Solid Tumor; Castration-Resistant Prostatic Cancer; Malignant Melanoma and 4 more
Sites: Los Angeles, California; San Francisco, California; Sarasota, Florida · 10 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07071961 · 16 participants (planned) · Start Feb 11, 2026 · Primary completion May 1, 2027
Drug: Regorafenib (CT); Lorigerlimab · For: Colorectal Cancer; Regorafenib; High Risk Patients
Sites: Houston, Texas
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07137390 · 0 participants · Start Sep 3, 2025 · Primary completion Jan 22, 2026
Drug: Regorafenib; Lorigerlimab · For: Colorectal Cancer
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07223567 · 0 participants · Start Oct 27, 2025 · Primary completion Jan 22, 2026
Drug: Regorafenib; Lorigerlimab · For: Rectal Cancer; Rectal Cancer Recurrent
Newest research
PubMed records naming it or its code names, newest first.
- Bispecific Dual-Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients.
Sina N, Muhaj F, Lenskaya V, et al. · J Cutan Pathol 2026
- Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium.
Jiang Y, Wu S, Li R, et al. · Exp Hematol Oncol 2023
- Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.
Berezhnoy A, Sumrow BJ, Stahl K, et al. · Cell Rep Med 2020
Also in development for Platinum-resistant Ovarian Cancer
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Rina-SPRO1184, GEN1184Phase 39 trials
Genmab · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer
- SYS6043Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, HCC - Hepatocellular Carcinoma
- ZN-c3azenosertibPhase 34 trials
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc · Ovarian Cancer, High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Uterine Serous Carcinoma
- Olvi-Vecolvimulogene nanivacirepvec, GL-ONCPhase 33 trials
Genelux Corporation · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer
- TaxanePhase 33 trials
AstraZeneca · Breast Cancer; HER2-positive; Metastatic, Solid Tumors, Platinum-resistant Ovarian Cancer
- NP-G2-044PrilukaePhase 32 trials
Novita Pharmaceuticals, Inc. · Platinum-resistant Ovarian Cancer, Advanced or Metastatic Solid Tumor Malignancies
- TILT-123Ad5, 3-E2F-d24-hTNFa-IRES-hIL2Phase 21 trial
TILT Biotherapeutics Ltd. · Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.